Tony’s Prostate Cancer Research - Cancer History in the Making

MDA & TPCR have identified a “CURE” for Prostate Cancer

The research supported by TPCR made a MAJOR BREAKTHROUGH in its discovery of GLIPR-1 - a protein, which naturally exists in our bodies, and acts as a natural suppressor to cancer development. As a protein it represents a non-toxic treatment for prostate cancer. It has been proven 100% effective in protecting against the growth of cancer in exposed animals, suppressing the continued growth of existing cancer cells and eliminating prostate cancer tumors in a laboratory setting with no side effects. MDA is proceeding through the process with the FDA for safety testing and eventual clinical trials.  The cure we have been seeking could be on the horizon !!!

THIS is what you and every supporter of TPCR can consider a part of your own legacy !!!

Since launching TPCR in 2002 your support has made it possible to resurrect the very promising research on the GLIPR1 protein which had been shelved due to funding cut-backs and have;

• Lead a paradigm-shift in research. Rethinking cancer therapy to use biological therapy…molecules your body produces to neutralize cancer cell reproduction. 
• Allowed MD Anderson to conduct in-vivo clinical trials in lab animals to find the therapeutic dose. 
• Seen researchers close-in on the event that starts cancer growth, identifying genes, diet and behaviors 
• Lead to Developing a method to make GLIPR1 protein modifications and purifications, which when injected systemically will allow it to seek-out prostate cancer cells and eradicate them. 
• Discovered that the presence of GLIPR1 facilitates the success of chemotherapy, increasing the response 100 fold in some cases. 

Research Scientist Dr. Timothy Thompson said. “Thanks to Tony Masraff what we are doing with the GLIPR1 is a paradigm shift in the medical community which couldn’t have been possible without your support and involvement over the years, Thank you Tony and all who support TPCR. This has been a life-changing experience for me and for all of us at MD Anderson.” Tony takes his role as Steward of your donated dollars very seriously. Under his scrutiny the funds donated by TPCR have been leveraged from 10 to 20 times their worth and are used solely for research.

In late 2011 a team of scientists with the FDA scrutinized the research of the MD Anderson team supported by TPCR for efficacy and safety, reviewed the clinical trial protocol and made recommendations. The challenge which lies ahead is to raise the monies needed to activate the process to produce the drug and perform abbreviated human trials. The process to begin to produce the drug that will be used in clinical trials is now underway. TPCR, with the support of the research team, is proceeding with fundraising efforts directed specifically at raising the monies needed for the Phase 1B trials. This Phase will require;

• manufacture of the GLIPR1 in a GMP (good manufacturing process) Environment
• re-testing of all animals involved in the laboratory tests, and
• clinical trials of a small group of high-risk prostate cancer patients

We expect this process to take 1.5 to 2 years and cost $3.0 to $3.5 million. To date TPCR has received over 50% of the needed funds and continues to hold informational meetings with interested donors to provide details on the research and our progress towards finding the “Cure”.

There are strong indications that the GLIPR1 protein could lead to major answers for not only prostate cancer, but other cancers as well, since it is present in both men and women.

Follow our progress by watching the funding graph that is now a part of TPCR’s website. We will also be updating our informational meeting dates on our website.

    $4,000,000      Target

                 $1,500,000       Raised to date

                $2,100,000       Commitments